3680609

Source:http://linkedlifedata.com/resource/pubmed/id/3680609

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0036341, umls-concept:C0042523, umls-concept:C0205160, umls-concept:C1292734, umls-concept:C1457887, umls-concept:C1522326, umls-concept:C1524063
pubmed:issue	5
pubmed:dateCreated	1988-1-11
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/8109496
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Haloperidol, http://linkedlifedata.com/resource/pubmed/chemical/Verapamil
pubmed:status	MEDLINE
pubmed:month	Oct
pubmed:issn	0271-0749
pubmed:author	pubmed-author:PascarziG AGA, pubmed-author:PriceW AWA
pubmed:issnType	Print
pubmed:volume	7
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	357
pubmed:dateRevised	2004-11-17
pubmed:meshHeading	pubmed-meshheading:3680609-Adult, pubmed-meshheading:3680609-Double-Blind Method, pubmed-meshheading:3680609-Haloperidol, pubmed-meshheading:3680609-Humans, pubmed-meshheading:3680609-Male, pubmed-meshheading:3680609-Middle Aged, pubmed-meshheading:3680609-Schizophrenia, pubmed-meshheading:3680609-Verapamil
pubmed:year	1987
pubmed:articleTitle	Use of verapamil to treat negative symptoms in schizophrenia.
pubmed:publicationType	Letter, Clinical Trial, Randomized Controlled Trial